Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLOBOTRK: Entrectinib in Children <3 Years With NTRK/ROS1-Fused CNS Tumors
NCT06528691Phase 2Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of entrectinib in glioma and central nervous system tumor, sponsored by St. Jude Children's Research Hospital. Primary endpoint: Overall Response Rate. Started May 2026; status: recruiting.
02
Drugs
entrectinib
03
Conditions
gliomacentral nervous system tumor
Beyond the preview
Go deeper on NCT06528691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06528691.